Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene, Agios Ready For Enasidenib Launch After Early Approval

Executive Summary

Idhifa is the first treatment for AML patients with IDH2 mutations. The drug will be co-commercialized by Celgene and Agios under their 2010 collaboration and is the latter's first regulatory approval.

Advertisement

Related Content

Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
Celgene's Partnered Pipeline Delivers Successes And Setbacks
US Approvals Analysis: Abbott Leads Another Strong Month For Novel Approvals
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Billions On The Line With Celgene’s Partnered Pipeline
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Cell Therapeutics To Launch First Commercial Product Trisenox With 16 Reps

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099246

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel